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Abstract Angiogenesis is critical to tumor growth as
well as to metastases. This process is tightly regulated by
pro- and anti-angiogenic growth factors and their receptors.
Some of these factors are highly specific for the endothe-
lium—e.g., vascular endothelial growth factor (VEGF).
A variety of drugs that target VEGF or its receptors have
been developed for the treatment of different tumor types
and a number of new agents is expected to be introduced
within the coming years. However, clinical experience has
revealed that inhibition of VEGF induces several side
effects including hypertension and renal and cardiac tox-
icity. Angiogenesis-inhibitor-induced hypertension repre-
sents ‘‘crux medicorum’’ as it is often pharmacoresistant to
antihypertensive therapy. We consider two most important
pathomechanisms in the development of hypertension
induced by angiogenesis inhibitors. The first represents
direct inhibition of NO production leading to reduced
vasodilatation and the second consists in increased prolif-
eration of vascular medial cells mediated by NO deficiency
and is resulting in fixation of hypertension. Based on the
results of experimental and clinical studies as well as on
our clinical experience, we assume that NO donors could
be successfully used not only for the treatment of devel-
oped angiogenesis-inhibitor-induced hypertension but also
for preventive effects. We thoroughly documented three
clinical cases of cancer patients with resistant hypertension
who on receiving NO donor treatment achieved target
blood pressure level and a good clinical status.
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Introduction
Vessel formation occurs mainly through two sequential
mechanisms: vasculogenesis—de novo formation of blood
vessels during embryonic development, and angiogene-
sis—formation of new capillaries from preexisting vessels
[1]. Angiogenesis is critical to tumor growth as well as to
metastases [2, 3]. This process is tightly regulated by pro-
and anti-angiogenic growth factors and their receptors.
Some of these factors are highly specific for the endothe-
lium (e.g., vascular endothelial growth factor—VEGF),
while others have a wide range of activities in different
cells (e.g., matrix metalloproteinases). A variety of physi-
ologic and pathologic stimuli can induce production of
angiogenic growth factors. Physiologic angiogenesis takes
place during tissue growth and repair, during the female
reproductive cycle, and during fetal development. In some
diseases, the body loses the ability to control angiogenesis
and new blood vessel growth is either excessive (e.g.,
cancer) or inadequate (e.g., coronary artery disease) [1–4].
As diseases relying on angiogenesis, such as cancer, are
often partially driven by VEGF, inhibition of angiogenesis
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as a therapeutic strategy against malignancies was proposed
by Folkman already in 1971 [5]. Meanwhile a variety of
drugs that target endothelial growth factor or its receptors
have been developed for the treatment of different tumor
types and the expectation is that a number of new agents
will be introduced within the coming years. VEGF receptors
(VEGFRs) are expressed mainly on endothelial cells. As
over 99 % of endothelial cells are quiescent under physio-
logical conditions, it was expected that angiogenesis inhi-
bition would have minimal side effects. However, clinical
experience has revealed that inhibition of VEGF induces
several side effects, including hypertension and renal and
cardiac toxicity [6]. Insight into the pathophysiological
mechanisms of these side effects is likely to contribute to
improved management of the toxicities associated with
VEGF inhibition. In this article we focus on the physiology
of VEGF, on pathophysiological mechanisms of angio-
genesis-inhibitor-induced hypertension and suggest a new
hypothesis on prevention and treatment of several side
effects of anti-angiogenic therapy.
VEGF, VEGF-receptors and their role in angiogenesis
Vascular endothelial growth factor, a 45 kDa glycoprotein,
is an angiogenic growth factor normally produced by
endothelial cells, podocytes, macrophages, fibroblasts, and
in malignancies by tumor cells or adjacent stroma. VEGF
165 (165 amino acids) is the predominant, biologically
most active isoform and is referred to as VEGF in this
review. The expression of VEGF is stimulated and regu-
lated by multiple factors including hypoxia, which repre-
sents the main stimulator of VEGF transcription mediated
through the hypoxia inducible factor 1 (HIF-1) [7, 8].
Transcription of the VEGF gene is inhibited by tumor
necrosis factor alpha (TNF-a). VEGF upregulates the
expression of endothelial nitric oxide synthase (eNOS) and
increases nitric oxide production. Nitric oxide, on the
contrary, may down-regulate VEGF expression via a neg-
ative feedback mechanism [9]. Tumor suppressor genes
and oncogenes have also been found to play an important
role in regulating VEGF gene expression. Loss or inacti-
vation of tumor suppressor genes, such as von Hippel-
Lindau (VHL), p53, p73, phosphatase and tensin homolog
(PTEN) and p16, as well as activated forms of oncogenes,
such as Ras, Src, human epidermal growth factor receptor 2
(HER2/neu) and breakpoint cluster region/Abelson (Bcr/
Abl), increase VEGF gene expression [10].
Vascular endothelial growth factor binds two tyrosine
kinase receptors, VEGF receptor 1 [VEGFR-1 or fms-like
tyrosine kinase (Flt-1) murine homologue] and VEGF
receptor 2 [VEGFR-2 or kinase domain region (KDR)
human homologue or Flk-1 murine homolog]. Both recep-
tors contain an extracellular region consisting of seven
immunoglobulin-like domains, a hydrophobic transmem-
brane domain and a cytoplasmatic bipartite tyrosine kinase
domain. VEGFR-1 and VEFGR-2 are expressed on endo-
thelial cells of most blood vessels, including those of pre-
glomerular, glomerular and peritubular vessels. Furthermore,
these receptors are present on hematopoietic stem cells,
circulating endothelial progenitor cells, dendritic cells, tro-
phoblasts, monocytes, retinal progenitor cells and certain
types of tumor cells [7, 11].
Most of the biologically relevant VEGF signaling in
endothelial cells is mediated by VEGFR-2, activated by
ligand-stimulated receptor dimerization and trans- (auto-)
phosphorylation of the tyrosine residues in the cytoplas-
matic domain [12]. The extracellular domain of Flt-1 is also
present as a soluble protein (sFlt-1) that inhibits angiogen-
esis by forming an inactive complex with circulating VEGF
[11]. VEGFR-1 has a 10-fold higher affinity for binding
VEGF than VEGFR-2 but autophosphorylation of the
tyrosine residues of the VEGFR-1 in response to VEGF
binding is weak [11]. VEGFR-1, like sFlt-1, has been sug-
gested to perform rather a decoy function by sequestering
VEGF and leaving less VEGF available for VEGFR-2 than
to mediate a mitogenic response [7]. VEGFR-3 (fms-like-
tyrosine kinase (Flt)-4) is also a member of the receptor
tyrosine kinases found mainly on lymphatic endothelium
and is important for lymphangiogenesis [7, 10].
Vascular endothelial growth factor exerts a variety of
biological activities. Its original name, vascular permeability
factor, indicates that it enhances permeability. Furthermore,
VEGF plays a key role in the mobilization of endothelial
progenitor cells from the bone marrow, in endothelial cell
proliferation, migration, survival and tube formation. It is a
potent stimulator of angiogenesis during embryogenesis,
menstrual cycle, wound healing and tumor growth. In addi-
tion, it inhibits antigen-presenting dendritic cells and stimu-
lates monocyte chemotaxis and the expression of adhesion
molecules. And finally, it induces vasodilation through
activation of the nitric oxide pathway [7]. The above men-
tioned activities of VEGF operate via several pathways,
including activation of the PI3 K/Akt (protein kinase B)/
mTOR pathway, partly mediating VEGF-induced nitric
oxide production via eNOS phosphorylation. Other actions
include activation of phospholipase C-c (PLC-c), protein
kinase C (PKC), Raf-1, extracellular-signal-regulated protein
kinase (ERK1/2), focal adhesion kinase (FAK) and mitogen-
activated protein kinase (MEK1/2) pathways [12–14].
Part of VEGF signaling occurs in a paracrine way,
which is essential for the proliferation, survival, perme-
ability responses and endothelial differentiation of the
angiogenic cascade. An autocrine signaling loop (cell-
autonomous) for VEGF is also required for survival of
blood vessels. Both paracrine and autocrine activation are
mediated by VEGFR-2 [15].
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Vascular endothelial growth factor has been shown to
induce endothelium-dependent vasorelaxation in arteries of
different sizes of various species, including human vessels
[16–19]. This vasodilatation appears to be mainly mediated
via nitric oxide, as it is attenuated in the presence of N-nitro-
L-arginine (L-NNA), a nitric oxide synthase inhibitor [16–18].
Endothelium-dependent vasodilation is mainly due to
VEGFR-2 stimulation [19]. In internal mammary arteries
obtained from patients with severe coronary artery athero-
sclerosis, both PGI2 and nitric oxide appeared to contribute
to VEGF-mediated vasorelaxation [18]. In addition to the
observed vasorelaxation in vitro, in vivo experiments
showed that intravenous injection of VEGF to conscious
male Sprague–Dawley rats resulted in a dose-dependent
decrease in mean arterial pressure and an increase in heart
rate, almost immediately after VEGF injection [19]. In
smooth muscle cells, nitric oxide may increase cGMP
leading to direct vasorelaxation and inhibit ribonucleotide
reductase resulting in decreased cell proliferation (Fig. 1).
Angiogenesis inhibitors
A variety of drugs targetting VEGF or its receptors have
been developed for the treatment of cancer, including
monoclonal antibodies to VEGF, small receptor tyrosine
kinase inhibitors (RTKIs) and circulating VEGF receptors
to trap VEGF (‘VEGF-Trap’) [16]. Bevacizumab is a
humanized monoclonal antibody that selectively binds
VEGF and was the first FDA-approved VEGF inhibitor for
systemic use in various forms of cancer including colo-
rectal, breast, renal and nonsquamous, non-small cell lung
cancer [20–22]. Bevacizumab has to be administered
intravenously, in contrast to the RTKIs such as sunitinib
(SU011248) and sorafenib (Bay 43-9006) which are suit-
able for oral administration. These agents are not selective
as they target a number of tyrosine kinases. For instance,
sunitinib inhibits VEGFR-1, VEGFR-2, VEGFR-3, platelet
derived growth factor (PDGFR)-a and PDGFR-b, c-KIT,
fms-like tyrosine kinase-3 (Flt3), colony stimulating factor
receptor type 1 and the glial-cell-line-derived neutrophic
factor receptor RET (rearranged during transfection). Suni-
tinib is approved for the treatment of imatinib-resistant
metastatic gastrointestinal stromal tumors (GIST) and first-
line treatment of metastatic renal cell carcinoma [23, 24].
Sorafenib is approved for the treatment of advanced renal
cell carcinoma after failure of interleukin-2 or interferon-a
treatment [23, 25]. The RTKIs are administered in cycles
according to a 4 weeks ‘‘ON’’ and 2 weeks ‘‘OFF’’ (wash-
out period) scheme. VEGFTrap (Regeneraon Pharmaceuti-
cals, Tarrytown, New York, USA) is a protein consisting
of portions of the extracellular domains of VEGFR-1 and
VEGFR-2, fused to the Fc-portion of human immunoglob-
ulin c1. It binds and thereby inactivates VEGF in the cir-
culation and tissues. The clinical effectiveness of this drug
has still to be determined [25].
Contrary to expectations, inhibition of VEGF is associated
with considerable cardiovascular and non-cardiovascular
toxicity, hypertension, left ventricular dysfunction, cardiac
ischemia, myocardial infarction, proteinuria, thyroid dys-
function, thrombosis, (cerebral) hemorrhage and skin mani-
festations, especially foot-hand syndrome.
Hypertension Induced by therapy with angiogenesis
inhibitors
The incidence of de novo or worsening hypertension in
association with antiangiogenic therapy varies between 17
and 90 % [26, 27]. Hypertension has been reported in up
to 36 % of patients during treatment with the humanized
VEGF antibody bevacizumab with blood pressure nor-
malization after treatment cessation [20, 28]. Initially reported
incidences of sunitinib-induced hypertension varied from 16
to 23 %, but more recent studies reported an incidence of up
to 47 % [29–32]. The incidence of hypertension was 67 %
with the combined treatment of bevacizumab and sorafenib
and 92 % with the combination of bevacizumab and sunitinib
in patients with advanced solid tumors or renal cell carcinoma
[33, 34]. Arterial hypertension in cancer patients can be
Fig. 1 Proposed pathways for the VEGF-induced induction of NO
synthesis in endothelial cells and the actions in smooth muscle cells.
VEGF induces immediate NO synthesis through the PLC-Ca2?/CaM
pathway and the induction of delayed NO synthesis implies Akt/PKB
and PKC activition (eNOS upregulation). In smooth muscle cells, NO
increases cGMP leading to vasorelaxation and inhibits ribonucleotide
reductase resulting in decreased proliferation
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associated with several complications, such as intracerebral
hemorrhages, acute heart failure, and reversible posterior
leukencephalopathy syndrome [30, 35, 36].
Mechanisms of hypertension
Although the mechanism underlying the development of
hypertension induced by angiogenesis inhibition still remains
to be elucidated, decreased nitric oxide bioavailability is
thought to be a critical factor. Results of the clinical study of
Robinson et al. [37] have suggested that hypertension induced
by VEGF inhibitors is mediated by suppression of NO
production.
The eNOS is regulated also by the level of intracellular
calcium. Intravascular calcium release by VEGF in vas-
cular endothelial cells results from phospholipase C (PLC-
c) activation, which subsequently generates diacylglycerol
(DAG) and activates inositol 1,4,5-triphosphate (IP3). IP3
induces the influx of calcium [38, 39]. The complex of
calcium and calmodulin associates with eNOS to cause
enzyme activation. The use of PLC inhibitors, CaM
antagonists or intracellular calcium chelators attenuated
Akt phosphorylation. Furthemore, the blockade of Ca/
CaM-dependent Akt phosphorylation abrogated immediate
NO production, whereas the inhibition of PI3K-dependent
Akt phosphorylation was unrelated to immediate NO pro-
duction. These data suggest that immediate NO synthesis
requires the Ca/CaM-dependent Akt pathway [14]. Because
eNOS is upregulated by VEGF, inhibition of VEGF by neu-
tralizing antibodies or a VEGFR blocker leads to a decrease in
nitric oxide production in endothelial cells that may account
for the development of hypertension [23].
Hovens et al. [40] measured flow-mediated and nitro-
glycerin-mediated dilatation of the brachial artery as respec-
tive measures of endothelial-dependent and independent
vasodilatation in patients treated with the experimental RTKI
telatinib (Bay 57-9352). After 5 weeks of treatment, systolic
and diastolic blood pressure were increased by respective 6.6
and 4.7 mmHg. This rise in blood pressure was associated
with a small decrease in flow-mediated dilatation of 2.1 %
and a decrease in nitroglycerin-mediated dilatation of 5.1 %.
Although reduced nitric oxide availability might have caused
the decrease in flow-mediated dilatation in this study, it
cannot be ruled out that the development of hypertension
itself had caused this reduction [40]. Of note, impaired nitric
oxide production may not only cause a generalized vaso-
constrictor response but may also affect renal sodium han-
dling, contributing to the maintenance of hypertension in the
longer run [41]. VEGF inhibitors might also lead to a
reduction in the vascular density and adversely alter micro-
circulation. Although the effect of anti-VEGF drugs on nitric-
oxide-dependent vasorelaxation is potentially reversible, the
rarefaction of capillaries might not be so and bears therefore
the risk of persisting hypertension [42, 43].
In essential hypertension, the activation of the renin–
angiotensin–aldosterone (RAS) system plays a pivotal role
and angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers (ARBs) are commonly used
for treatment. Whether the RAS is also activated in anti-
VEGF-drug-induced arterial hypertension remains contro-
versial [13]. Veronese et al. [44] reported that neither the
renin-angiotensin system nor the sympathetic nervous sys-
tem were involved in the development of this hypertension.
Other factors influencing VEGF- inhibitors-induced hyper-
tension include host susceptibilities, such as preexisting
hypertension. Whether the type of cancer, and particularly
renal cell cancer, is associated with a higher risk of anti-
VEGF-induced hypertension remains controversial [45].
According to the results of our experimental studies, inhi-
bition of nitric oxide synthase led to systemic hypertension
with focal myocardial fibrosis, impaired arterial relaxation,
and uncontrolled vascular medial proliferation attributed to
the absence of smooth muscle cell proliferation inhibition by
NO [46]. Mechanisms responsible for the antiproliferative
effect of NO may involve cGMP-dependent and -indepen-
dent phases acting at distinct points in the cell cycle, e.g.,
nitric oxide inhibits ribonucleotide reductase by cGMP-
independent manner [47].
On the basis of experimental and clinical studies, we
postulated the existence of at least two pathophysiological
mechanisms leading to hypertension in patients treated
with inhibitors of angiogenesis: (1) direct inhibition of NO
production leading to reduced vasodilatation and increased
vasoconstriction; (2) NO- deficiency-mediated increase in
proliferation of vascular medial cells leading to the fixation
of hypertension. Based on these two potential mechanisms,
we assume that it would be possible to avoid hypertensive
complications by using NO donors in patients treated with
inhibitors of angiogenesis.
Case reports
We present three case reports from our clinical practice
corroborating the validity of our hypothesis.
Case No.1: A 67-year-old caucasian male was diagnosed
of colorectal cancer with liver metastases without severe
cardiovascular disease in history. He received chemother-
apy, which consisted of a combination of 5-fluorouracil,
leucovorin, irinotecan, and bevacizumab, an inhibitor of
angiogenesis. After the second course of chemotherapy,
hypertension developed in the patient. Blood pressure
ranged from 180 to 210 mmHg systolic and from 100 to
120 mmHg diastolic. Despite comprehensive antihyper-
tensive therapy based on administration of angiotensin
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converting enzyme inhibitors, thiazide diuretics, calcium
channel blockers, beta-blockers and spironolactone, his
blood pressure values ranged from 170 to 180 mmHg
systolic and from 100 to 110 mmHg diastolic. Thereafter,
the patient was treated with the NO donor molsidomine and
we found a significant decrease in blood pressure values
from 130 to 140 mm Hg systolic and 70 to 85 mmHg
diastolic. This antihypertensive effect persisted over a long
time following the seven months since introduction of the
treatment.
Case No.2: A 59-year old caucasian male, a smoker, was
treated for non-small cell lung cancer. In the past he had
pulmonary artery embolism and was also treated for chronic
gastritis. Due to cancer, left sided lobar lung resection was
performed followed by adjuvant chemotherapy. Chemo-
therapy was based on a combination of cis-platin, vinorel-
bine and bevacizumab. Three weeks after the initiation of
chemotherapy, hypertension resistant to antihypertensive
treatment developed. Antihypertensive treatment was based
on a combination of five drugs—angiotensin converting
enzyme inhibitors, calcium channel blockers, beta blockers,
thiazide diuretics and centrally acting hypotensives. Despite
this therapy, systolic blood pressure was between 150 and
170 mmHg and diastolic from 95 to 110 mmHg. After
addition of the NO donor isosorbide dinitrate, the clinical
condition of the patient improved and his blood pressure
decreased significantly to 130 mmHg systolic and 85 mmHg
diastolic.
Case No. 3 was a 69-year old caucasian male with relapsed
locally advanced renal cell carcinoma with metastases in the
liver. After combined chemotherapy including avastin, he
developed pharmacoresistant hypertension. Initially his
blood pressure values ranged from 170 to 190 mmHg systolic
and from 90 to 110 mmHg diastolic blood pressure, with
currently administered combined antihypertensive therapy
(ACE inhibitors, beta blockers, calcium channel blockers,
thiazide diuretic, spironolactone). After adding isosorbide
mononitrate to the treatment, a decrease of blood pressure to
130–140 mmHg systolic and 80–90 mmHg diastolic was
monitored. The therapeutic response persisted even 6 months
after treatment initiation.
Conclusion
We assume two most important pathomechanisms opera-
tive in the development of hypertension induced by angi-
ogenesis inhibitors. The first represents direct inhibition of
NO production leading to reduced vasodilatation, and the
second consists in the increased proliferation of vascular
medial cells mediated by NO deficiency and resulting in
fixation of hypertension. Moreover, NO deficiency may
negatively affect the anticancer process itself. We used
successfully NO donors in the treatment of hypertension in
three cancer patients whose hypertension was a side effect
of anti-angiogenic therapy and was resistant to the anti-
hypertensive treatment administered. Based on the results
of experimental and clinical studies as well as our clinical
experience, we assume that the NO donors could be suc-
cessfully used not only for the treatment of developed
angiogenesis-inhibitor-induced hypertension but also as a
preventive measure.
Perspectives
Administration of NO donors before chemotherapy with
angiogenesis inhibitors and/or during chemotherapy could
significantly reduce the incidence and severity of this type of
hypertension. The suggested approach may present a break-
through in antihypertensive therapy focusing on pharmaco-
therapeutic prevention of hypertension in cancer patients
receiving inhibitors of angiogenesis. Clinical studies are
however needed to confirm the validity of this hypothesis.
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